Opdivo

Merck’s Keytruda picks up third approval for NSCLC in China

However, it was not the first PD-1 inhibitor to get a green light in the country – Bristol-Myers Squibb won that prize for Opdivo (nivolumab) in NSCLC back in 2018.

Roche’s Tecentriq/Avastin combo improves survival in liver cancer

HCC could be another important indication for Tecentriq as it plays catch-up in the cancer immunotherapy market with Merck &Co/MSD’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo ... BMS meanwhile reported data a few months ago from the

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Bristol-Myers Squibb has faced a bump in the road of its expansion plans for Opdivo/Yervoy, after the combination failed to demonstrate a significant benefit in certain high-risk melanoma ... However, BMS has recently  announced positive results from

MSD’s Keytruda scores another EU okay, in head and neck cancer

new treatment option and MSD’s drug another leg up over its rivals in the checkpoint inhibitor category such as Bristol-Myers Squibb’s Opdivo (nivolumab). ... Keytruda also overtakes Opdivo in HNSCC, which at the moment is only approved as a

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

BMS has previously evaluated Opdivo as a monotherapy treatment in front-line lung cancer, although its efforts in this area were fruitless. ... However, BMS is likely hoping that its upcoming $74bn takeover of Celgene will reduce its reliance on Opdivo

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]